Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways… Read more
Compass Therapeutics Inc. (CMPX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.052x
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has a cash flow conversion efficiency ratio of -0.052x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.85 Million) by net assets ($209.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Compass Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Compass Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Compass Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
-0.230x |
|
Critical Metals Corp. Ordinary Shares
NASDAQ:CRML
|
-0.065x |
|
Hoang Anh Gia Lai JSC
VN:HAG
|
0.172x |
|
Lotte Energy Materials Corporation
KO:020150
|
-0.008x |
|
Meren Energy
ST:MER
|
0.166x |
|
Muangthai Capital Public Company Limited
BK:MTC
|
-0.046x |
|
Foshan Nationstar Optoelectronics Co Ltd
SHE:002449
|
0.024x |
|
F&F Co Ltd
KO:383220
|
0.049x |
Annual Cash Flow Conversion Efficiency for Compass Therapeutics Inc. (2018–2024)
The table below shows the annual cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.23 Million | $-44.85 Million | -0.358x | -30.98% |
| 2023-12-31 | $148.54 Million | $-40.62 Million | -0.273x | -45.55% |
| 2022-12-31 | $181.64 Million | $-34.12 Million | -0.188x | -33.82% |
| 2021-12-31 | $140.08 Million | $-19.67 Million | -0.140x | +79.08% |
| 2020-12-31 | $39.95 Million | $-26.80 Million | -0.671x | -350.72% |
| 2019-12-31 | $-118.60 Million | $-31.74 Million | 0.268x | -32.64% |
| 2018-12-31 | $-84.77 Million | $-33.68 Million | 0.397x | -- |